covid
Buscar en
Gaceta Médica de Bilbao
Toda la web
Inicio Gaceta Médica de Bilbao El valor pronóstico de la reactividad cutánea retardada en la supervivencia a ...
Journal Information
Vol. 99. Issue 4.
Pages 92-96 (January 2002)
Share
Share
Download PDF
More article options
Vol. 99. Issue 4.
Pages 92-96 (January 2002)
Full text access
El valor pronóstico de la reactividad cutánea retardada en la supervivencia a 10 años en el cáncer colorrectal: un estudio prospectivo / Larruazaleko erreaktibotasun atzeratuaren pronostiko-balioa ondeste-koloneko minbizitik bizirik atera eta handik 10 urtera: azterketa etorkizunari begira
Prognostic significance of delayed sensitivity skin test in colorectal carcinoma: a 10 year prospective study
Larruazaleko erreaktibotasun atzeratuaren pronostiko-balioa ondeste-koloneko minbizitik bizirik atera eta handik 10 urtera: azterketa etorkizunari begira
Visits
1450
M. Echenique
Corresponding author
gepecelm@sc.ehu.es

Correspondencia: Miguel Echenique Elizondo. Medikuntz Irakaskuntza Gunea. Universidad del País Vasco - Euskal Herriko Unibersitatea. Dr. Begiristain Pasealekua, 105. 20014 Donostia-San Sebastián. Tel.: +34 943017319 - Fax: +34 943017330
Departamento de Cirugia. Universidad del País Vasco.
This item has received
Article information
Resumen

El propósito del estudio es determinar si la respuesta inmunocelular medida mediante reactividad cutánea pueda tener un valor p ronóstico en el cáncer colorrectal.

Material y Metodos

Se analiza de forma prospectiva y a 10 años una serie de 77 pacientes intervenidos de cáncer colorrectal en diferentes estadíos histopatológicos –A=4, B=19, C=49 y D=5– trata dos en un mismo hospital y con los mismos criterios durante un período de 2 años. La supervivencia a los 10 años fue de 4/4 en el estadio A, 7/19 (36,8%) en el B, 8/49 (16,32%) en el C y 0/50 (0%) en el D. Se determinó preoperatoriamente, a las 48 horas postoperatorias y a los 30 días la reactividad cutánea retardada a un conjunto de antígenos Multitest (r).

Resultados

El estudio de los datos una vez conocida la supervivencia real a 10 años la reactividad cutánea preoperatoria, medida en mm, resulta significativa en cuanto al pronóstico para pacientes en estadios B p<0,05 - y C p<0,01

Conclusión

La determinación numérica de la reactividad cutánea retardada preoperatoria parece constituir un índice de valor pronóstico en el cáncer colorrectal en estadíos B y C.

Palabras clave:
Cancer
colon
recto
inmunidad
supervivencia
Summary

The aim of the study was to determine if the cell-mediated immune response may have any prognostic signification in cancer of the colon and rectum.

Material and Methods

A series of 77 patients operated for cancer of the colon and rectum in the same hospital and with identical criteria during two years are analyzed prospectively for a ten year follow up. Dukes stages were -A=4, B=19, C=49 y D=5. Survival according stages was: 4/4 in stage A, 7/19 (36.8%) B, 8/49 (16.32%) C y 0/50(0%) D. Before operation and 48 h. thereafter and at 30 days cell-mediated immune reactivity skin test was done trough a multiple antigen compouind -Multitrst-R.

Results

Comparison of preoperative numeric results according staging with a control group demonstrates, a significative diference for patients stage B and very significative for stage considering patients alive and death at ten years.

Conclusion

Cell-mediated immune reactivity skin test measured preoperatively may represent a prognostic factor y cancer of the colon and rectum for stages B and C.

Key words:
Cancer
colon
rectum
survival
inmunity
cell-mediated
Laburpena

Hona zer zuen helburu ikerlan honek: larruazaleko erreaktibotasunaren bidez neurtutako erantzun immunozelularrak ondeste-koloneko minbizian pronostiko-baliorik ba ote duen jakitea.

Materiala eta metodoak

Etorkizunari begira (hamar urteko epean) 77 gaixo aztertu dira, guztiak ere ondeste-koloneko minbiziagatik ebakuntza egin zaienak eta hainbat estadio histopatologikotan daudenak -A-n=4, B-n=19, C-n=49 eta D-n=5-, ospitale berean, irizpide berberak erabilita, bi urtez tratatuak. Honakoa zen hamar urteren buruan bizirik zeuden gaixoen proportzioa: 4tik 4 A estadioan (%100); 19tik 7 (% 36,8) B-n; 49tik 8 (% 16,32) C-n eta 5etik bat ere ez (% 0) D estadioan. Ebakuntza egin aurretik eta ebakuntza egin eta handik 48 ordura zein 30 egunera zehaztatu zen larruazaleko erreaktibotasun atzeratua hainbat antigenorekiko -Multitest (R)-.

Emaitzak

B -p<0,05- eta C -p<0,01- estadioetako gaixoen pronostikorako -hamar urterako benetako biziraupena zein den jakin ondoren- adierazgarria da ebakuntza aurreko larruazaleko erreaktibotasuna (mm-tan neurtua).

Ondorioak

Ebakuntza aurreko larruazaleko erreaktibotasun atzeratuaren zenbakizko zehaztapena pronostiko-balioa da, antza, B eta C estadioetako ondeste-koloneko minbizian.

Hitz adierazgarriak:
Minbizia
kolona
ondestea
inmunitatea
biziraupena
Full text is only aviable in PDF
Referencias bibliográficas
[1.]
O'Brien M.J..
Cancer of the colon and rectum: current concepts of aethiology and pathogenesis.
Br J Med Sci, 157 (1988), pp. 5-15
[2.]
Echenique Elizondo M., Amondarain L., Liron De Robles C..
El valor pronóstico de la reactividad cutánea retardada en la supervivencia a 5 años en el cáncer colorrectal.
Rev Esp Enf Digest, 87 (1995), pp. 843-848
[3.]
Dukes C.E..
The classification on cancer of the rectum.
J Pathol Bacteriol, 35 (1932), pp. 323-329
[4.]
Kirklin J.W., Dockerty M.B., Waugh J.M..
The role of peritoneal reflection in the prognosis of carcinoma of the rectum and sigmoid colon.
Surg Gynecol Obstet, 88 (1949), pp. 326-330
[5.]
Astler V.B., Coller F.A..
The prognostic significance of direct extension of carcinoma of the colon and rectum.
Ann Surg, 139 (1954), pp. 846-857
[6.]
Fisher E.R., Robinsky B., Sass R., Fisher B..
Relative prognostic value of the Dukes and the Jass system in rectal cancer: Finding from the National Surgical Adjuvant Breast and Bowell Proyects.
Dis Col Rectum, 32 (1989), pp. 944-949
[7.]
American Joint Comitee On Cancer.
Manual for staging cancer, JB Lippincott Ed, (1983),
[8.]
Pheils M.T., Barnett J.E., Newland R., Mc Pherson J..
Colorectal carcinoma: A prospective clinico-pathologycal study.
J Pathol Bacteriol, 1 (1976), pp. 17-21
[9.]
Terrazas J., Val-Bernell J., Buelta L..
Surg Gynecol Obstet, 165 (1987), pp. 255-259
[10.]
Jass J.R., Atkin W.S., Cruzick J., Bussey H.J., Morson B.C., Northover J.M., et al.
The grading of rectal cancer: historical prespectives and a multivariante analysis of 447 cases.
Histopathology, 10 (1986), pp. 437-459
[11.]
Díaz Aguirregoitia F.J., García-Alonso I., Iturburu I., Portugal Porras V., Alonso Varona A., Echeverría García-Sanfrechoso A., et al.
Valor pronóstico del ADN nuclear en 106 tumores colorrectales medido por microespectrofotometría.
Rev Esp Enf Digest, 83 (1993), pp. 421-428
[12.]
Armitage N.C.M., Ballantyne K.C., Sheffield J.P., Clarke P., Evans D.F., Hardcastle J.D..
A prospective evaluation of the effect of tumor-cell DNA content on recurrence in colorectal cancer.
Cancer, 67 (1991), pp. 2599-2604
[13.]
Hiddeman W., Von Basewitz D.B., Kleinemeier H.J., et al.
DNA steam-line heterogeneity in colorectal cancer.
Cancer, 58 (1986), pp. 258-263
[14.]
Gómez-Alonso A., García J., Orfao De Matos A..
El análisis de ADN mediante citometría de flujo en patología colorrectal maligna.
Cir Esp, 50 (1991), pp. 132-136
[15.]
Böttger T.C., Gabbert H.E., Stöckle M., Welleck S., Hils R., Heintz A., et al.
DNA image cytometry: A prognostic tool in rectal cancer.
Dis Col Rectum, 35 (1992), pp. 436-443
[16.]
Temple W.J., Sugarbaker E.V., Thornwaite J.T., Hensley G.T., Ketcham A.S..
Correlation of cell-cycle analysis with Duke's staging in colon cancer patients.
J Surg Res, 28 (1980), pp. 314-318
[17.]
Kashtan H., Papa M.Z., Stern L.S..
Is age an independent variable in the morbidity and mortality of patients with colorectal cancer? A prospective clinico-pathologycal study.
Can J Surg, 34 (1991), pp. 374-376
[18.]
Krasma M.J., Flancbaum L., Cody R.D., Sheinbaum S., Ari G.B..
Vascular and neural invasion in colorectal cancer: incidence and prognostic significance.
Cancer, 61 (1988), pp. 1018-1023
[19.]
Rankin F.W., Broders A.C..
Factors influencing prognosis in carcinoma of the rectum.
Surg Gynecol Obstet, 46 (1928), pp. 660-667
[20.]
Van Den Ingh H.F., Ruiter D.J., Griffoen G., Van Muijen S., Ferrone S..
HLA antigens in colorectal tumors: low expression of HLA class I antigens in mucinous colorectal carcinomas.
Br J Cancer, 55 (1987), pp. 125-130
[21.]
Minton J.P., Hoehn J.L., Gerber D.M., et al.
Results of a 400 patients carcinoembryonic antigen second look colorectal cancer study.
Cancer, 55 (1985), pp. 1284-1290
[22.]
Aviram R., Deutsh A., Patya M., et al.
Biochemical tissue markers of human colorectal carcinoma.
Dis Col Rectum., 3 (1988), pp. 176-180
[23.]
Moore M., Jones D.J., Scholfield P.F., Harndern D.O..
Current status of tumor markers in large bowell cancer.
World J Surg, 13 (1989), pp. 52-59
[24.]
Chazelet C., Baumel H., Deixonne B., Daures J.M., Saissi G..
Prognostic factors of surgically-treated cancers of the right colon.
Multifactorial analysis of 50 curative excisiones. J Chir (Paris), 126 (1989), pp. 81-84
[25.]
Vose B.M., Gallagher P., Moore M., Schoffield P.F..
Specific and non-specific lymphocite cytotoxicity in colon carcinoma.
Br J Cancer, 44 (1981), pp. 846-855
[26.]
Triozzi P.L., Kim J.A., Aldrich W., Young D.C., Sampsel J.W., Martin E.W. Jr..
Localization f tumor reactive lymph node lymphocytes in vivo using radio-labeled monoclonal antibodies.
Cancer, 73 (1994), pp. 560-589
[27.]
House A.K., Watt A.G..
Survival and immune response in patients with carcinoma of the colorectum.
Gut, 20 (1979), pp. 868-874
[28.]
Barbera Guillem E., Arnold M.W., Nelson M.B., Martin E.W. Jr.
First result for resetting the antitumor immune response by immune corrective surgery in colon cancer.
Am J Surg, 176 (1998), pp. 339-343
[29.]
Nieroda C.A., Arnold M.W., Barbera-Guillem E., Martin E.W..
Lymphadenectomy in colorectal carcinoma.
Chirurg, 69 (1998), pp. 717-724
[30.]
Vermorken J.B., Laesen A.M., van Tinteren H., Gall H.E., Ezinga R., Meijer S., et al.
Active specific immunotherapy for stage I and stge III human colon cancer: a randomised trial.
[31.]
Kahan B.D., Pellis N.R., Rutzky L.P., Wiseman F., Tom B.H..
Active specific immunoherapy potential for treatement of large bowell cancer.
Cancer, 40 (1977), pp. 2740-2746
[32.]
Patel B.T., Lutz M.B., Schlag P., Schirrmacher V..
An analysis of autologous T-cell anti-tumor responses in colon-carcinoma patients following active specific immunization.
Int J Cancer, 51 (1992), pp. 878-885
[33.]
Maric M., Liu Y..
Cytotoxic T lymphocyte responses to a macrophage inflammatory protein 1-alpha-expressing tumor: linkage between inflammatory and specific immunity.
Cancer Res, 5 (1999), pp. 5549-5553
[34.]
Ohtani H., Naito Y., Saito N., Nagura H..
Expression of costimulatory molecules B7-1 and B7-2 by macrophages along invasive margin of colon cancer: a possible antitumor immunity.
Lab Invest, 77 (1997), pp. 231-241
[35.]
Staren E.D., Economou S.G., Harris J.E., Braun D.P..
Lymphokine-activated killer cell induction in tumor-infiltrating leukocytes from colon cancer patients.
Cancer, 64 (1989), pp. 2238-2240
[36.]
Jacob L., Somasundaram R., Smith W., Monos D., Basak S., Marincola F., et al.
Cytotoxic T-cell clone against rectal cell carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumor cells.
Int J Cancer, 71 (1997), pp. 325-332
[37.]
Nind A.P., Mathews N., Phil A.e.A., Rolland J.M., Nairn R.C..
Analysis of inhibition of lymphocyte cytotoxicity in human colon carcinoma.
Br J Cancer, 31 (1975), pp. 6220-6629
[38.]
Dukes C.E., Bussey H.J.R..
The spread of rectal cancer and its effect on prognosis.
Br J Cancer, 12 (1958), pp. 309-320
[39.]
Enker W.E., Heilweil H.L., Hertz R.E., et al.
En bloc pelvic lymphadenectomy and sphincter preservation in the surgical management of rectal cancer.
Ann Surg, 203 (1986), pp. 426-433
[40.]
Michelassi F., Block G.E., Vannucci L., Montag A., Chappell R..
A 5 to 21 years follow-up and analysis of 250 patients with rectal adenocarcinoma.
Ann Surg, 206 (1988), pp. 379-389
[41.]
Calvo Sancho J.J., Lamata F.A., Garcia Gil F.A., Lagos Lizan J., Cerda R., Ortiz Solórzano J., González González M..
Cirugía del cáncer de recto. Aspectos terapeúticos y de supervivencia. Análisis retrospectivo de dos décadas.
Cir Esp, 54 (1993), pp. 423-429
[42.]
Celaya Pérez S..
Estudio de la relación entre presuntas variables antropométricas y bioquímicas de la nutrición y la respuesta inmune en el enfermo quirúrgico, Doktore-tesia, (1983),
[43.]
Jaurrieta E., Sitges Serra A., Sánchez Ortega J.M., Sitges Creus A..
Desnutrición e inmunodepresión preoperatoria. Factores de riesgo en cirugía mayor.
Cir Esp, 35 (1981), pp. 81-86
[44.]
Aviron R., Rodez J..
The delayed hypersensitivity response as a prediction of outcome of surgical operation. Dogma disputed.
Br J Surg, 67 (1980), pp. 368-370
[45.]
Cainzos M., Fernández Seara J., Potel J.L..
Pruebas de hipersensibilidad retardada en pacientes quirúrgicos y complicaciones sépticas postoperatorias.
Cir Esp, 38 (1984), pp. 48-52
[46.]
Riboli E.B., Terrizzi A., Arnulfo G., et al.
Immunosuppressive effect of surgery evaluated by the Multitest cell mediated immunity system.
Can J Surg, 27 (1984), pp. 19-25
[47.]
Heys S.D., Park K.G.M., Garlick P.J., Eremin O..
Nutrición y enfermedad neoplásica maligna. Sus implicaciones en la práctica quirúrgica.
Br J Surg, 79 (1992), pp. 614-623
[48.]
Daly J.M., Dudrick S.J., Copeland E.M..
Intravenous alimentation. Effect on delayed cutaneous sensitivity in cancer patients.
Ann Surg, 192 (1980), pp. 563-587
[49.]
Twoney P., Ziegler D., Dombeau J..
Utility of skin testing in nutritional assesement. A critical review.
JPEN, 6 (1982), pp. 50-58
[50.]
Meakins J.L., Piestch J.B., Bubenick O., et al.
Delayed hypersensitivity: Indication of adquired faliure of host defenses in sepsis and trauma.
Ann Surg, 186 (1977), pp. 241-244
[51.]
Bjorklholm M., Holm G., Mellstedt H..
No effect of delayed cutaneous hypersensitivity testing (Multitest) on blood limphocyte count and function.
Acta Med Scand, 214 (1983), pp. 399-403
[52.]
McLean L.D., Meakins J.L., Taguchi K., et al.
Host resistance in sepsis and trauma.
Ann Surg, 182 (1975), pp. 207-217
[53.]
Fernández Seara J., Cainzos M., Potel J., Puente Domínguez J.L..
Estudio de los posibles factores asociados con el estado de anergia y anergia relativa en pacientes quirúrgicos.
Cir Esp, 38 (1984), pp. 37-45
[54.]
Cainzos M., Potel J.Y., Puente J.L..
Valoración del estado de anergia con el Multitest(r) en pacientes quirúrgicos.
Rev Quir Esp, 15 (1988), pp. 12-18
[55.]
Mc Lean L.D., Meakins J.L., Taguchi K., et al.
Delayed hipersensitivity response: Application in clinical surgery.
Surgery, 82 (1977), pp. 349-355
[56.]
García Sabrido J.L., Medina M.C., Quintans A..
Perfil inmunológico en pacientes quirúrgicos.
Cir Esp, 37 (1983), pp. 353-355
[57.]
Johnson W.C., Ulrich F., Meguid M.M., et al.
Role of delayed hypersensitivity in predicting postoperative morbidity and mortality.
Am J Surg, 137 (1979), pp. 536-541
[58.]
Christow N.V., Meakins J.L., McLean L.D..
The predicted role of delayed hypersensitivity in preoperative patients.
Surg Gynecol Obstet, 152 (1981), pp. 297-301
[59.]
Bolton D.M., Mandel A.M., Davidson J.M., et al.
Celular inmunity in cancer: Comparison of delayed hypersensitivity test in three common cancers.
Br Med J, 3 (1975), pp. 18-29
[60.]
Dominioni L., Dionigi R., Dionigi D., Nazari S., Fossati G.S., Prati V., Tibaldeschi C., Pavasi F..
Evaluation of possible causes of delayed hyper-sensitivity impairment in cancer patients.
JPEN, 5 (1981), pp. 300-306
Copyright © 2002. Academia de Ciencias Médicas de Bilbao
Article options